Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
The patient missed the fourth dose of Vivotif; Case reference number US-BN-2025-001419 is a spontaneous case initially received from a consumer via Communication (reference number: USBAV25-2059) on 19-Aug-2025 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified dates, the patient took first three doses of Vivotif (batch number: unknown) at an unknown dose, route, or site of administration for typhoid prophylaxis, and missed to take the fourth dose (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A male patient of unspecified age missed to take the fourth dose of Vivotif for typhoid prophylaxis, which is considered as missed dose. It was unknown if the patient experienced any adverse events due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age missed to take the fourth dose of Vivotif for typhoid prophylaxis, which is considered as missed dose. It was unknown if the patient experienced any adverse events due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE